Indolent B Cell Lymphoma - 25 Studies Found

Completed : Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
: Lymphoma, Non-Hodgkin
: 2009-07-30
: Biological: tositumomab and Iodine I 131 tositumomab (anti-B1 antibody) For the treatment of 1st or 2nd
Active, not recruiting : Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Indolent B-cell Lymphoma, Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma
:
  • Leukemia
  • Lymphoma

: 2009-08-20
:
  • Drug: Bortezomib Starting dose
Active, not recruiting : Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
: Leukemia
: 2007-04-25
:
  • Biological: therapeutic autologous lymphocytes
Terminated : A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
:
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, B-Cell

: 2008-10-06
: Drug: AEG35156 antisense IV infusion AEG35156 will be give
Active, not recruiting : A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
:
  • Indolent B-cell Lymphoma
  • Chronic Lymphocytic Leukaemia
    • : 2013-03-04
    : Drug: DI-B4 DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose wi
Active, not recruiting : Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
:
  • Leukemia
  • Lymphoma
  • Multiple Myeloma and Plasma Cell Neoplas
    : 2009-07-08
    :
    • Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell
Recruiting : Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
:
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Follicular
  • Lymphoma, Mantl
    : 2014-09-30
    :
    • Drug: Rituximab 375 mg/m2 I.V.
Completed : Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
: Lymphoma
: 2004-10-06
: Drug: bortezomib + rituximab Arm I: Patients receive borte
Completed : Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
: Lymphoma
: 2005-11-22
:
  • Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine
Completed : Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
: Lymphoma
: 2000-01-21
:
  • Biological: keyhole limpet hemocyanin
  • Biol
<<< Previous | Next >>>